In this context, the class I HDAC inhibitor mocetinostat was recently shown to inhibit the expression of ZEB1, to upregulate its target, miR‐203, and to restore sensitivity to chemotherapy in pancreatic cancer cells (Meidhof et al, 2015). Here, ZEB1 is linked to familial pancreatic carcinoma.